PhiC31/PiggyBac modified stromal stem cells: effect of interferon γ and/or tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) on murine melanoma

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Bahrambeigi, Vahid ^a,b   Ahmadi, Nafiseh ^a   Moisyadi, Stefan ^c,d   Urschitz, Johann ^c   Salehi, Rasoul ^b   Haghjooy Javanmard, Shaghayegh ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF HAWAII   (United States)

^d Manoa BioSciences   (United States)

Author keywords

Adipose derived mesenchymal stem cell; Interferon ; Murine melanoma; PhiC31 integrase; PiggyBac transposase; TRAIL

Indexed keywords

GAMMA INTERFERON; JANUS KINASE; PHIC31 RECOMBINASE; PIGGYBAC TRANSPOSASE; PROGRAMMED DEATH 1 LIGAND 1; RECOMBINASE; STAT1 PROTEIN; TRANSPOSASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; INTERLEUKIN 2; NERVE PROTEIN;

ADIPOSE DERIVED MESENCHYMAL STEM CELL; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CD4+ CD25+ FOXP3+ T REGULATORY CELL; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL SURVIVAL; CONTROLLED STUDY; DNA INTEGRATION; ENZYME ACTIVATION; FLOW CYTOMETRY; HISTOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MALE; MELANOMA; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; C57BL MOUSE; LUNG TUMOR; MCF 7 CELL LINE; METABOLISM; PHYSIOLOGY; STEM CELL; STROMA CELL; TUMOR CELL LINE;

MURINAE; MUS;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; LUNG NEOPLASMS; MALE; MCF-7 CELLS; MELANOMA; MICE; MICE, INBRED C57BL; NERVE TISSUE PROTEINS; RECOMBINASES; SIGNAL TRANSDUCTION; STEM CELLS; STROMAL CELLS; T-LYMPHOCYTES, REGULATORY; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSPOSASES;

EID: 84935020338     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-255     Document Type: Article

References (51)

1. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M: Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002,62(13):3603-3608.
2. Keravala A, Ormerod BK, Palmer TD, Calos MP: Long-term transgene expression in mouse neural progenitor cells modified with phiC31 integrase. J Neurosci Methods 2008,173(2):299-305.
3. Hackett PB: Integrating DNA, vectors for gene therapy. Mol Ther 2007,15(1):2-10.
4. Hollis RP, Stoll SM, Sclimenti CR, Lin J, Chen-Tsai Y, Calos MP: Phage integrases for the construction and manipulation of transgenic mammals. Reprod Biol Endocrinol 2003, 1:79.
5. Wu SC, Meir YJ, Coates CJ, Handler AM, Pleczar P, Moisyadi S, Kaminski JM: PiggyBac is a flexible and highly active transposon as compared to sleeping beauty, Tol2, and Mos1 in mammalian cells. Proc Natl Acad Sci U S A 2006,103(41):15008-15013.
6. Urschitz J, Kawasumi M, Owens J, Morozumi K, Yamashiro H, Stoytchev I, Marh J, Dee JA, Kawamoto K, Coates CJ, Kaminski JM, Pelczar P, Yanagimachi R, Moisyadi S: Helper-independent piggyBac plasmids for gene delivery approaches: strategies for avoiding potential genotoxic effects. Proc Natl Acad Sci U S A 2010,107(18):8117-8122.
7. Ikeda H, Old LJ, Schreiber RD: The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002,13(2):95-109.
8. Jonasch E, Haluska FG: Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001,6(1):34-55.
9. Park SY, Seol JW, Lee YJ, Cho JH, Kang HS, Kim IS, Park SH, Kim TH, Yim JH, Kim M, Billiar TR, Seol DW: IFN-gamma enhances TRAIL-induced apoptosis through IRF-1. Eur J Biochem 2004,271(21):4222-4228.
10. Grisendi G, Bussolari R, Cafarelli L, Petak I, Rasini V, Veronesi E, De Santis G, Spano C, Tagliazzucchi M, Barti-Juhasz H, Scarabelli L, Bambi F, Frassoldati A, Rossi G, Casali C, Morandi U, Horwitz EM, Paolucci P, Conte P, Dominici M: Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res 2010,70(9):3718-3729.
11. Fulda S, Debatin KM: IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene 2002,21(15):2295-2308.
12. Lissat A, Vraetz T, Tsokos M, Klein R, Braun M, Koutelia N, Fisch P, Romero ME, Long L, Noellke P, Mackall CL, Niemeyer CM, Kontny U: Interferon-gamma sensitizes resistant Ewing's sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity. Am J Pathol 2007,170(6):1917-1930.
13. Yang X, Merchant MS, Romero ME, Tsokos M, Wexler LH, Kontny U, Mackall CL, Thiele CJ: Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB. Cancer Res 2003,63(5):1122-1129.
14. Langaas V, Shahzidi S, Johnsen JI, Smedsrod B, Sveinbjornsson B: Interferon-gamma modulates TRAIL-mediated apoptosis in human colon carcinoma cells. Anticancer Res 2001,21(6):3733-3738.
15. Lee J, Shin JS, Choi IH: Human brain astrocytes mediate TRAIL-mediated apoptosis after treatment with IFN-gamma. Yonsei Med J 2006,47(3):354-358.
16. Johnsen JI, Pettersen I, Ponthan F, Sveinbjornsson B, Flaegstad T, Kogner P: Synergistic induction of apoptosis in neuroblastoma cells using a combination of cytostatic drugs with interferon-gamma and TRAIL. Int J Oncol 2004,25(6):1849-1857.
17. Zeytin H, Reali E, Zaharoff DA, Rogers CJ, Schlom J, Greiner JW: Targeted delivery of murine IFN-gamma using a recombinant fowlpox virus: NK cell recruitment to regional lymph nodes and priming of tumor-specific host immunity. J Interferon Cytokine Res 2008,28(2):73-87.
18. Elzaouk L, Moelling K, Pavlovic J: Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model. Exp Dermatol 2006,15(11):865-874.
19. Kucerova L, Matuskova M, Pastorakova A, Tyciakova S, Jakubikova J, Bohovic R, Altanerova V, Altaner C: Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. J Gene Med 2008,10(10):1071-1082.
20. Ren C, Kumar S, Chanda D, Chen J, Mountz JD, Ponnazhagan S: Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells 2008,26(9):2332-2338.
21. Liu J, Jeppesen I, Nielsen K, Jensen TG: Phic31 integrase induces chromosomal aberrations in primary human fibroblasts. Gene Ther 2006,13(15):1188-1190.
22. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, Goodwin RG: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995,3(6):673-682.
23. Igney FH, Krammer PH: Immune escape of tumors: apoptosis resistance and tumor counterattack. 2002;71(6):907-20. 26. J Leukoc Biol 2002,71(6):907-920.
24. Takahashi K, Takeda K, Saiki I, Irimura T, Hayakawa Y: Functional roles of TRAIL-DR5 interaction in B16F10 by activating NFkappaB pathway to induce metastatic potential. Cancer Sci 2013,104(5):558-562.
25. Abdel-Wahab Z, Weltz C, Hester D, Pickett N, Vervaert C, Barber JR, Jolly D, Seigler HF: A phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response. Cancer 1997,80(3):401-412.
26. Nemunaitis J, Bohart C, Fong T, Meyer W, Edelman G, Paulson RS, Orr D, Jain V, O'Brien J, Kuhn J, Kowal KJ, Burkeholder S, Bruce J, Ognoskie N, Wynne D, Martineau D, Ando D: Phase I trial of retroviral vector-mediated interferon (IFN)-gamma gene transfer into autologous tumor cells in patients with metastatic melanoma. Cancer Gene Ther 1998,5(5):292-300.
27. Nemunaitis J, Fong T, Robbins JM, Edelman G, Edwards W, Paulson RS, Bruce J, Ognoskie N, Wynne D, Pike M, Kowal K, Merritt J, Ando D: Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma. Cancer Gene Ther 1999,6(4):322-330.
28. Li X, Lu Y, Huang W, Xu H, Chen X, Geng Q, Fan H, Tan Y, Xue G, Jiang X: In vitro effect of adenovirus-mediated human gamma interferon gene transfer into human mesenchymal stem cells for chronic myelogenous leukemia. Hematol Oncol 2006,24(3):151-158.
29. Schmitt MJ, Philippidou D, Reinsbach SE, Margue C, Wienecke-Baldacchino A, Nashan D, Behrmann I, Kreis S: Interferon-gamma-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells. Cell Commun Signal 2012,10(1):41.
30. Beatty GL, Paterson Y: Regulation of tumor growth by IFN-gamma in cancer immunotherapy. Immunol Res 2001,24(2):201-10.
31. Jin HT, Ahmed R, Okazaki T: Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol 2011,350(6):17-37.
32. Yang W, Chen PW, Li H, Alizadeh H, Niederkorn JY: PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro. Invest Ophthalmol Vis Sci 2008,49(6):2518-2525.
33. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC: Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010,207(10):2187-2194.
34. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF: Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci Transl Med 2013,5(200):116-200.
35. Kakuta S, Tagawa Y, Shibata S, Nanno M, Iwakura Y: Inhibition of B16 melanoma experimental metastasis by interferon-gamma through direct inhibition of cell proliferation and activation of antitumour host mechanisms. Immunology 2002,105(1):92-100.
36. Correll A, Tuettenberg A, Becker C, Jonuleit H: Increased regulatory T-cell frequencies in patients with advanced melanoma correlate with a generally impaired T-cell responsiveness and are restored after dendritic cell-based vaccination. Exp Dermatol 2010,19(8):213-221.
37. Yanez R, Lamana ML, Garcia-Castro J, Colmenero I, Ramírez M, Bueren JA: Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells 2006,24(11):2582-2591.
38. West EE, Jin HT, Rasheed AU, Penaloza-Macmaster P, Ha SJ, Tan WG, Youngblood B, Freeman GJ, Smith KA, Ahmed R: PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J Clin Invest 2013,123(6):2604-2615.
39. Wagner B, Henschler R: Fate of intravenously injected mesenchymal stem cells and significance for clinical application. Adv Biochem Eng Biotechnol 2013, 130:19-37.
40. Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI, Laine GA, Cox CS Jr: Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev 2009,18(5):683-692.
41. Eggenhofer E, Benseler V, Kroemer A, Popp FC, Geissler EK, Schlitt HJ, Baan CC, Dahlke MH, Hoogduijn MJ: Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol 2012, 3:297.
42. Kraitchman DL, Tatsumi M, Gilson WD, Ishimori T, Kedziorek D, Walczak P, Segars WP, Chen HH, Fritzges D, Izbudak I, Young RG, Marcelino M, Pittenger MF, Solaiyappan M, Boston RC, Tsui BM, Wahl RL, Bulte JW: Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. Circulation 2005,112(10):1451-6110.
43. Kyriakou C, Rabin N, Pizzey A, Nathwani A, Yong K: Factors that influenceshort-term homing of human bone marrow-derived mesenchymal stem cells in axenogeneic animal model. Haematologica 2008,93(10):1457-1465.
44. Kurtz A: Mesenchymal stem cell delivery routes and fate. Int J Stem Cells 2008,1(1):1-7.
45. Eggenhofer E, Luk F, Dahlke MH, Hoogduijn MJ: The life and fate of mesenchymal stem cells. Front Immunol 2014,19(5):148.
46. Kidd S, Spaeth E, Dembinski JL, Dietrich M, Watson K, Klopp A, Battula VL, Weil M, Andreeff M, Marini FC: Direct evidence of mesenchymal stem cell tropismfor tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 2009,27(10):2614-2623.
47. Li L, Jiang Q, Ding G, Zhang L, Zhang ZG, Li Q, Panda S, Lu M, Ewing JR, Chopp M: Effects of administration route on migration and distribution of neural progenitor cells transplanted into rats with focal cerebral ischemia, an MRI study. J Cereb Blood Flow Metab 2010,30(3):653-662.
48. D'souza N, Burns JS, Grisendi G, Candini O, Veronesi E, Piccinno S, Horwitz EM, Paolucci P, Conte P, Dominici M: MSC and tumors: homing, differentiation, and secretion influence therapeutic potential. Adv Biochem Eng Biotechnol 2013, 130:209-266.
49. Comsa S, Ciuculescu F, Raica M: Mesenchymal stem cell-tumor cell cooperation in breast cancer vasculogenesis. Mol Med Rep 2012,5(5):1175-1180.
50. Groth AC, Fish M, Nusse R, Calos MP: Construction of transgenic Drosophila by using the site-specific integrase from phage phiC31. Genetics 2004,166(4):1775-1782.
51. Marh J, Stoytcheva Z, Urschitz J, Sugawara A, Yamashiro H, Owens JB, Stoytchev I, Pelczar P, Yanagimachi R, Moisyadi S: Hyperactive self-inactivating piggyBac for transposase-enhanced pronuclear microinjection transgenesis. Proc Natl Acad Sci U S A 2012,109(47):19184-19189.